C

Celyad Oncology
CYAD

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
€16.41M
EV
€13.11M
Shares Outstanding
41.74M
Beta
1.07

Wall Street View

Analyst Rating
NOT_AVAILABLE
Analyst Target Price
-
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Celyad Oncology SA

gainify

C

Celyad Oncology SA

CYAD

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of ...

Sector

Healthcare

Industry

Biotechnology

CEO

Kane, Matthew

Employees

18

IPO Date

2013-07-04

Headquarters

Axis Business Park, Rue AndrE Dumont 9, Mont-Saint-Guibert, Walloon Brabant, 1435, Belgium

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.